Tissue Factor Pathway Inhibitor Activity in Human Plasma
Toshinori Kokawa(National Cerebral and Cardiovascular Center), Hisao Kato(National Cerebral and Cardiovascular Center), Mariko Harada‐Shiba(Osaka University of Pharmaceutical Sciences), Takeo Abumiya(Hokkaido University), Motoo Tsushima(National Cerebral and Cardiovascular Center), Takashi Kimura(Fukushima Medical University), Hideki KOH(Institute for Atherosclerosis Research), Akira Yamamoto(Juntendo University)
Cited by 51
Related Papers
Matrix Metalloproteinases Increase Very Early during Experimental Focal Cerebral Ischemia
|Journal of Cerebral Blood Flow & Metabolism|1999|552
Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel
|The Lancet Diabetes & Endocrinology|2016|418
2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance
|European Heart Journal|2023|329
Lymphocyte-C-reactive Protein Ratio as Promising New Marker for Predicting Surgical and Oncological Outcomes in Colorectal Cancer
|Annals of Surgery|2019|298
Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022
|Journal of Atherosclerosis and Thrombosis|2023|269